Quest Diagnostics

  • 3 Dividend Stocks Boasting High Free Cash Flow Yields

    By Chris Johnson - August 14, 2013 | Tickers: MRVL, OMI, DGX

    Free cash flow (FCF)—or owner earnings, as it is referred to by the legendary investor Warren Buffett—represents the cash available to shareholders after all other claims have been met. Based on FCF, a good measure of the fundamental strength of a company is its FCF yield, which is calculated by dividing a company’s FCF per share by its current market price per share. A positive FCF yield more »

  • Which of these Companies is Ready for Inpatient Influx?

    By Phillip Woolgar - August 10, 2013 | Tickers: HCA, DGX, THC

    Health care providers are positioned to make major profits in the years ahead due to changes on several fronts, including ObamaCare, an improving economy and an aging baby boom. These companies haven't experienced the type of uptake they were expecting so far this year, and this could be because health care reform doesn't really kick in until next year, when patients will be able to enjoy medical coverage more »

  • Why This Health Care Play Looks Like a Good Value

    By Lee Samaha - June 14, 2013 | Tickers: AET, CI, HOLX, LH, DGX

    I'm more of a GARP orientated investor but I occasionally I dabble in some value stocks. I confess I get tempted by the sordid infidelity of it all. 

    A few years ago a well known UK fund manager outlined one approach to the art of value investing to me. In short it involved analyzing companies across a sector and finding one that was under-performing based on various key metrics more »

  • 5 Dividend Stocks Boasting High Free Cash Flow Yields

    By Meena Krishnamsetty - May 22, 2013 | Tickers: BLC, KLAC, MRVL, OMI, DGX

    Free cash flow (FCF)—or owner earnings, as it is referred to by the legendary investor Warren Buffett—represents the cash available to shareholders after all other claims have been met. Based on FCF, a good measure of the fundamental strength of a company is its FCF yield, which is calculated by dividing a company’s FCF per share by its current market price per share. A positive FCF yield more »

  • Collecting Dividends From the Healthcare Sector

    By Ash Anderson - April 27, 2013 | Tickers: BAX, PFE, DGX

    Continuing on with the dividend trend that my recent articles have been focusing upon, I’d like to now take a look at some solid healthcare companies. These companies must meet two strict criteria in that they must be profitable, and they must pay a dividend. That’s not too harsh, right? Well, away we go into the wild world of healthcare!

    Major drug manufacturers

    You had to guess that more »

  • Key Earnings for the Week (April 15)

    By Lee Samaha - April 15, 2013 | Tickers: GOOG, INTC, IBM, JNJ, DGX

    After a quiet opening week to earnings season, this week brings a torrent of earnings reports from Dow components and industry bellwethers.

    Monday

    Monday starts with Citigroup reporting, and it’s going to kick off a big week for financials.

    Tuesday

    The banking theme continues on Tuesday with Comerica and Goldman Sachs reporting numbers. We also have three bellwethers reporting.

    In healthcare, Johnson & Johnson (NYSE: JNJ) will update investors on more »

  • Dividend Boost for Apple?

    By Mark Morelli - March 20, 2013 | Tickers: AAPL, FHN, IBM, PAYX, DGX, AES, WMT

    According to a recent survey conducted by Bloomberg the technology giant Apple (NASDAQ: AAPL), the world's most valuable and profitable company, is poised to increase its dividend. 

    Analysts polled indicated that Apple, which resumed paying a dividend in August 2012 after a hiatus of many years, will spend nearly $16 billion in 2013 and raise its quarterly payout by over half to $4.14 a share. The resulting 3 more »
  • Why This Stock Is an Interesting Value Play

    By Lee Samaha - January 25, 2013 | Tickers: LH, DGX

    Diagnostic testing company Quest Diagnostics (NYSE: DGX) caught my eye recently. It’s always nice to balance a portfolio by deliberately buying stocks whose prospects are not cyclically aligned, and Quest seems to fit the bill. In summary, the stock price driver is likely to be a combination of its internal reorganization plans plus the top line effect of reimbursement issues. It does have some cyclical upside from an improving more »

  • Searching for the Next Franchise in Diagnostic Testing

    By Robert Hanley - January 25, 2013 | Tickers: GNMK, LIFE, DGX

    Ever since the human genome was completely sequenced in 2001, investment opportunities have abounded in the diagnostic testing industry, as exciting, new technologies have been built around this important scientific discovery.  The increasingly recurring nature of the testing business, and its strong profit margins, have brought private equity firms to the sector in search of buyouts.  The latest target is Life Technologies (NASDAQ: LIFE), which recently announced that it was more »

  • Buy This Wide-Moat Company

    By Ted Cooper - January 8, 2013 | Tickers: ALR, LH, DGX

    Companies that provide diagnostic lab testing for hospitals and managed care providers have been hit hard by the economic downturn, as many patients are visiting the doctor less often than they used to. However, this trend will likely reverse itself as the United States economy recovers and Obamacare is fully implemented.

    In the United States, diagnostic lab testing is dominated by two companies: Quest Diagnostic (NYSE: DGX) and LabCorp (NYSE: LHmore »)

  • The Price is Right at Quest Diagnostics

    By Steve Van - September 12, 2012 | Tickers: BRLI, LH, DGX

    Quest Diagnostics Inc. (NYSE: DGX) and Laboratory Corporation of America (NYSE: LH) are two giants in the diagnostic testing business which is experiencing shifting domestic population demographics, changing laws and regulations, and changing customer preferences.  Another player in the industry is the much smaller Bio-Reference Laboratories Inc. (NASDAQ: BRLI) which operates primarily in metro New York.  Quest's position as the market leader should result in above market returns for more »

  • 4 Stocks Insiders are Buying this Week

    By Meena Krishnamsetty - August 12, 2012 | Tickers: DAL, LOGI, DGX, WWD

    Company insiders often have a better perspective of the company’s future performance than outside investors do.  Furthermore, they have an incentive to diversify their investments away from their employer so that negative company-specific events don’t result in a hit to both their income and to their wealth. So when an insider buys a stock, it should be evidence that the company has good times ahead- and statistically this more »

  • Quest or Labcorp – How About a Smaller Option?

    By Chad Henage - January 26, 2012 | Tickers: BRLI, LH, DGX

    When most people are asked by their doctor where they would like to go to get their blood drawn or a test done the choices are usually Quest Diagnostics (NYSE: DGX) or Labcorp (NYSE: LH). These two titans of the testing and analysis industry have more locations and are generally well known. In beginning to write this I expected to compare these two and see which looked like the better buy. Then something happened, I realized they have a much smaller competitor that is crushing both of their results. Who is this small fry in the same business? - Bio-Reference Laboratories (NASDAQ: BRLI).